Azra AI Expands Innovative Incident Finding Technology to Help Clinicians Identify More Cancers

Clinical Intelligence Platform covers liver, kidney and adrenal gland, thyroid, pancreatic and ovarian cancer, aneurysms

FRANKLIN, Tenn.July 6, 2022 /PRNewswire/ — Azra AI’s proprietary software — which uses artificial intelligence (AI) and natural language processing to identify incidental lung nodules in medical reports — is expanding to include liver, kidney and adrenal, pancreatic and ovarian cancers and aneurysms.

Azra AI logo (PRNewsfoto/Azra AI)

Azra AI logo (PRNewsfoto/Azra AI)

Azra AI’s platform is expanding to identify liver, kidney and adrenal, pancreatic and ovarian cancers and aneurysms.

Now in use in more than 200 medical systems and hospitals across the country, Azra AI’s technology is helping clinicians and medical teams identify suspicious findings that could lead to an earlier diagnosis of cancer for patients, with treatment options enabling patients to to cure. These findings are detected in patients who primarily receive imaging for other diseases or health care conditions, which explains the term ‘incidental’. Azra AI’s technology identifies cancers that often have no symptoms until the cancer is at a late stage.

A groundbreaking study of 1,000 computed tomography (CT) scans ordered by emergency room clinicians — led by researchers at the University of Utah School of Medicine – found that follow-up for incidental lung nodules was 29%, a poor overall rate. Researchers said these rates remain low even when there are specific instructions for patients to follow. Up to 80% of lung nodules are found incidentally and almost a quarter of those nodules are malignant.

Chris CashwellAzra AI CEO, said the expanded platform will positively impact the lives of more people.

“With this wider scope of incidental findings, our technology will help physicians, navigators and healthcare teams more quickly identify potential cancers at a critical time,” he said. “Health equity is a key priority for health systems and targeting incidental findings is a great way to influence the quality and consistency of care for patients. We are proud to partner with some of the leading health systems across the country that using the technology, including HCA Healthcare and University of Pennsylvania health system. †

Detecting ovarian and other cancers as quickly as possible is critical, making Azra AI technology all the more important for medical systems, hospitals and their patients.

Women with ovarian cancer usually present with: symptoms easily confused with other more common conditions, including constipation or a urinary tract infection. Five Year Survival prices for certain ovarian cancers are relatively low, underscoring the importance of early detection. In addition, there is a dramatic 93% reduction in survival from early detection to less than 30% when the cancer has spread.

The number of people affected by these cancers is significant. Lung cancer is the third most common cancer in the US, with estimates of 236,740 new cases and 130,180 deaths in 2022. The National Cancer Institute estimates 62,210 new cases and 49,830 deaths for pancreatic cancer. About 79,000 new cases of kidney cancer are expected in 2022, with an estimated 13,920 deaths.

Brook Blackmore, Vice President of Clinical Operations at Azra AI, previously served as senior director of navigation operations at Sarah Cannon, HCA Healthcare’s cancer institute. She helped create today’s technology, working with a core team at Azra AI, and has seen its impact firsthand.

“We are excited to offer deep AI and natural language processing technologies to help even more patients,” she said. “Having worked as a clinician and leader in cancer care, I recognize the importance of this comprehensive platform. Clinicians and navigators in health systems using the Azra AI platform can now devote more time to patients, ensuring timely follow-up and patient retention for treatment.”

According to an 2018 Journal of Clinical Oncology studyAzra AI technology used in three HCA hospital markets resulted in a 35% increase in time allocated to direct patient contact and physician interaction.

About Azra AI

Azra AI uses proprietary artificial intelligence software to read millions of unstructured data records and identify at-risk patients in need of follow-up care, resulting in more equitable health outcomes, increased patient retention, and reduced burden on clinical workers. This revolutionary technology — used in hospitals and cancer centers across the country — accelerates the patient care process and positively impacts clinical, financial and operational outcomes. Learn more about Azra AI https://www.azra-ai.com/ and follow us at @Azra_AI_Health.

Contact: KNB Communication
E-mail: [email protected]
Phone: (203) 504-8230

decide

decide

View original content to download multimedia:https://www.prnewswire.com/news-releases/azra-ai-expands-innovative-incidental-findings-technology-to-help-clinicians-identify-more-cancers-301581087.html

SOURCE Azra AI

Leave a Comment

Your email address will not be published.